利用醇功能化的生物粘性混合纳米脂质体,用于性结肠炎局部治疗
Kanika1, Anas Ahmad2, Ajay Kumar1
1Chemical Biology Unit, Institute of Nano Science and Technology, Sector 81, Knowledge City, Sahibzada Ajit Singh Nagar, Mohali, Punjab, 140306, India.
Biomaterials
|August 14, 2024
概括
装有酸的新纳米脂质体通过粘附于炎症结肠,减少炎症和促进愈合,克服传统阴囊疗法的局限性,改善了性结肠炎 (UC) 治疗.
科学领域:
- 纳米技术纳米技术
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 性结肠炎 (UC) 治疗面临着挑战,因为药物保留和吸收不良,传统的阴囊疗法面临挑战.
- 现有的方法难以在结肠中持续输送药物,导致效率和副作用变化.
研究的目的:
- 开发新型的化粘粘粘性阴离子纳米脂质体,用于将酸 (GA) 特定地传递到炎症的肠部位.
- 为了克服性结肠炎常规阴囊治疗的局限性.
主要方法:
- 酸载荷的化离子纳米脂质体 (GATh@APDL) 的发展,大小约为100nm.
- 在体外和体内评估纳米脂质体粘附和治疗疗效的结肠炎模型.
- 通过测量NF-κB,HIF-1α和MMP-9等关键生物标志物以及MUC2蛋白表达来评估抗炎作用.
主要成果:
- 化纳米脂质体表现出延长的停留时间和增强对炎症结肠组织的粘附性.
- GATh@APDL显著减轻了结肠炎症,降低了NF-κB,HIF-1α和MMP-9的表达.
- 该配方通过增加MUC2表达和减少炎症细胞透来促进粘膜的愈合.
结论:
- 酸载 2,6 DALP DMPG (GATh@APDL) 为性结肠炎提供了一个有前途的向药物输送系统.
- 这种纳米脂质体配方克服了传统阴道的局限性,在减少炎症和促进结肠愈合方面表现出卓越的疗效.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
131
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
131
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
103
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
103
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
417
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
417
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
01:26Peptic Ulcer Disease IV: Management
78
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
78